| 11-Jun-2007 | S | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 11, 2007, has approved the sub-division of the equity shares of the Company from Rs 2/- per share to Re 1/- per share, subject to the approval of the shareholders by way of Postal Ballot.
Glenmark Pharmaceuticals Ltd has informed BSE that the members of the Company have approved through Postal Ballot the following resolutions at the deemed Extraordinary General Meeting (EGM) held on July 27, 2007, with requisite majority :
1. Sub-Division of Equity Shares from the face value of Rs 2/- per share to Re l/_ per share and consequent change in the Capital clause of the Memorandum of Association.
(As Per BSE Announcement Website Dated on 27/07/2007)
SUB. :- Sub Division of equity shares of Glenmark Pharmaceuticals Limited (Scrip Code 532296)
Trading members of the Exchange are hereby informed that, Glenmark Pharmaceuticals Limited has fixed the Book Closure for the purpose of sub division of equity shares of the company.
COMPANY NAME
CODE
Glenmark Pharmaceuticals Limited
532296 & 632296
BOOK CLOSURE DATE 17/09/2007 to 20/09/2007
SUB-DIVIDED PAID-UP VALUE Re.1/-
SUB-DIVIDED PAID-UP VALUE W.E.F.
10/09/2007 DR-114/2007-2008
PURPOSE
Sub Division of existing equity shares from every ONE equity share of Rs.2/- each into TWO equity shares of Re.1/- each.
The auction in the equity shares of Glenmark Pharmaceuticals Limited in Dematerialised Securities - Rolling Settlement Segment on 10/09/2007, 11/09/2007 and 12/09/2007 will be conducted as per face value of Rs.2/- each. Trading members are, therefore, requested to take abundant precautions while mentioning the rates for offering the equity shares of the said company in auction on the said dates.
The scrip will be No Delivery from 10/09/2007 (DR-114/2007-2008) to 14/09/2007 (DR-118/2007-2008).
Note :-
i. Trading members are hereby informed that the transactions in the equity shares (physical) of the aforesaid company in the Exit-Route Scheme will be for Re.1/- paid up w.e.f. 10/09/2007.
ii. ISIN No. INE935A01027 of Rs.2/- paid up will not be valid for transactions done on the Exchange on or after 10/09/2007, except for the auction transactions, which will be conducted on 10/09/2007, 11/09/2007 and 12/09/2007 respectively.
iii. The new ISIN Number for Re.1/- paid up will be informed to the market by a separate notice.
(As per BSE Notice dated on 29/08/2007) | 17-Sep-2007 | |
| 07-Oct-2003 | S | Sub Division of existing equity shares from every ONE existing equity share of Rs.10/- each into Five equity shares of Re.2/- each.
REDUCED PAID-UP VALUE - Rs.2/-
REDUCED PAID-UP VALUE W.E.F. - 23/10/2003 | 31-Oct-2003 | |
| 24-May-2024 | D | Recommended Dividend @ 250% i.e. Rs. 2.5/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2023-24 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 13-Sep-2024 | |
| 19-May-2023 | D | Recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2022-23 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
| 18-Sep-2023 | |
| 28-May-2022 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 27, 2022, inter alia, has recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2021- 22 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 12-Sep-2022 | |
| 28-May-2021 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 28, 2021, inter alia, has recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2020 - 21 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 08-Sep-2021 | |
| 26-Jun-2020 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 26, 2020, inter alia, has recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2019 - 20 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 17-Sep-2020 | |
| 29-May-2019 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on May 29, 2019, inter alia, has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2018-19 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 19-Sep-2019 | |
| 29-May-2018 | D | The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on May 29, 2018 has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2017 - 2018 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 19-Sep-2018 | |
| 11-May-2017 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 11, 2017, inter alia, has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2016 - 2017 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 20-Sep-2017 | |
| 12-May-2016 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 12, 2016, inter alia, has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2015-2016 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 03-Aug-2016 | |
| 29-May-2015 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2015, inter alia, have recommended Dividend @ 200% i.e. Rs. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2014 - 2015 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 10-Sep-2015 | |
| 08-May-2014 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 08, 2014, inter alia, has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2013-2014 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 10-Jul-2014 | |
| 07-May-2013 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 07, 2013, inter alia, has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2012-2013 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 18-Jul-2013 | |
| 08-May-2012 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 08, 2012, inter alia, has recommended Dividend @ 200% i.e. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2011-2012 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 19-Jul-2012 | |
| 10-May-2011 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 10, 2011, inter alia, recommended Dividend @ 40% i.e. Re. 0.40 per share (Face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2010-2011 subject to the approval of the Shareholders at the ensuing Annual General Meeting. | 28-Jul-2011 | |
| 28-May-2010 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 28, 2010, inter alia, has recommended Dividend @ 40% (Re. 0.40 per share of Re. 1 face value) subject to the approval of Shareholders. | 16-Sep-2010 | |
| 26-Jun-2009 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 26, 2009, inter alia, has recommend Dividend @ Re 0.40 (face value Rs 1/-) on the Equity Share Capital of the Company for the financial year 2008-2009 subject to the approval of the Shareholders at the Annual General Meeting. | 10-Sep-2009 | |
| 31-Oct-2007 | D | Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 31, 2007, inter alia, has transacted the following:
1. Declared Interim dividend @ 70% on the Equity Share Capital of the Company for the financial year 2007-08. | 07-Nov-2007 | |
| 26-Dec-2006 | D | 40% Interim Dividend | 04-Jan-2007 | |
| 15-Apr-2005 | D | 35% Interim Dividend | 27-Apr-2005 | |
| 21-Feb-2005 | B | Members of the Exchange are hereby informed that, Glenmark Pharmaceuticals Ltd. has fixed the Book Closure Dates for Bonus Issue. The transactions in the equity shares of the company should be done on an ex-bonus basis with effect from the undermentioned date.
ONE Bonus share for every ONEexisting equity share held. | 08-Mar-2005 | 1:1 |
| 30-Oct-2024 | BC | GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve the Unaudited Financial Results o | 14-Nov-2024 | |
| 30-Aug-2024 | BC | AGM 27/09/2024 | 27-Sep-2024 | |
| 30-Aug-2024 | BC | Rs.2.5000 per share(250%)Final Dividend& A.G.M,.. | 17-Sep-2024 | |
| 30-Aug-2024 | BC | 250% Final Dividend | 13-Sep-2024 | |
| 31-Jul-2024 | BC | GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve the Unaudited Financial Results o | 14-Aug-2024 | |